Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease
American Journal of Physiology-Renal Physiology 321(2):F149-F161, 2021
Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH
International Journal of Molecular Sciences 22:6332, 2021
Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice
Scientific Reports 11:8060, 2021
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis
Liver International 41(8):1853-1866, 2021
Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis
British Journal of Pharmacology 178(12):2412-2423, 2021
Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in db/db mice
Biomedicine & Pharmacotherapy 133:110966
3D quantification of changes in pancreatic islets in mouse models of diabetes type I and II
Disease Models & Mechanisms 13(12):dmm045351, 2020